MARKSANS Marksans Pharma Q4 FY26 results (Jan–Mar 2026) and concall
Marksans Pharma delivered a strong Q4 and FY26, achieving its highest-ever profitability with FY26 operating revenue of INR2,951 crores and an EBITDA margin of 20.4%. The company reported robust growth across key geographies, particularly North America and Australia, and remains debt-free with substantial cash reserves. While anticipating raw material cost inflation and rising logistics costs in Q1 FY27, management reaffirmed its target of INR4,000 crores revenue by FY28 and is actively pursuing M&A opportunities to drive future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 21.1%, net profit up 142.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 309 | 312 | 299 | 320 | 320 +4% | 340 +9% | 362 +21% |
| EBITDA | 63 | 60 | 52 | 70 | 72 +14% | 75 +25% | 106 +104% |
| Net profit | 63 | 55 | 38 | 48 | 100 +59% | 61 +11% | 92 +142% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
